[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antimicrobial-resistance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antimicrobial-resistance":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,84,110,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100543669","phase-4-azithromycin-for-child-survival-in-niger-ii-100543669",false,"NCT06358872","Azithromycin for Child Survival in Niger II","Azithromycine Pour la Vie Des Enfants au Niger II","AVENIR II","Inclusion Criteria:\n\nCSI-level for mortality and AMR monitoring:\n\n* Located in a region participating in the program\n* Designated as rural by local study team\n* Selected for participation in monitoring activities\n* Safe and accessible for study teams\n* Verbal approval from community leaders\n\nIndividual level for mortality monitoring:\n\n* Residing in the catchment area of an eligible CSI\n* Selected for participation in monitoring activities\n* Female\n* Age between 12 and 55 years old\n* Verbal approval from participant\n\nIndividual-level for AMR monitoring:\n\n* Residing in the catchment area of an eligible CSI\n* Selected for participation in monitoring activities\n* Age between 1 and 59 months old\n* Verbal approval from a caregiver or guardian\n\nExclusion Criteria:\n\nAt the community-level:\n\n* Designated as urban by local study team\n* Inaccessible or unsafe for study team\n\nAt the individual-level:\n\n* Known allergy to macrolides",true,"ALL","1 Month","59 Months",{"count":22,"type":23},3300000,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","Several randomized controlled trials have demonstrated that azithromycin mass drug administration (MDA) reduces child mortality, but increases antimicrobial resistance (AMR). The World Health Organization (WHO) guidelines for this intervention specify that implementation must be accompanied by continued monitoring of mortality and AMR. Niger is expanding the azithromycin MDA program nationwide. To establish monitoring of mortality and AMR as part of this program as well as to leverage the infrastructure to evaluate other child health interventions, AVENIR II is designed as an adaptive platform trial with monitoring and re-randomization every 2 years.",[29,30],"Mortality","Antimicrobial Resistance",[32,33,34,30,35],"Mass Treatment","Azithromycin","Childhood Mortality Rate","Implementation and Cost Analysis","RECRUITING","2026-08-13",{"date":39,"type":40},"2026-08-17","ACTUAL",{"date":42,"type":40},"2024-04-29",{"date":44,"type":23},"2028-04-29",{"name":46,"class":47},"University of California, San Francisco","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":60,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":48},"100646938","molecular-microbiology--guided-antimicrobial-stewardship-versus-standard-stewardship-in-hospitalized-patients-100646938","NCT07684300","Molecular Microbiology- Guided Antimicrobial Stewardship Versus Standard Stewardship in Hospitalized Patients","Impact of Molecular Microbiology Integrated With Clinical Data on Antimicrobial Therapy Optimization: An Open-Label Cluster-Randomized Crossover Trial","PROACT","Inclusion Criteria:\n\n* Age ≥18 years\n* Hospitalized in one of the participating study units at Hospital General Universitario de Elche.\n* Initiation of empiric high-impact antimicrobial therapy subject to antimicrobial stewardship program (ASP) review.\n* Provision of written informed consent by the participant or, when applicable, by a legally authorized representative.\n\nExclusion Criteria:\n\n* Severe immunosuppression with profound neutropenia (\\\u003C100 neutrophils\u002Fmm³).\n* Previous enrollment in this clinical trial.\n* Expected survival of less than 48 hours.\n* Documented microbiological identification of the presumed causative pathogen by conventional methods in a representative and\u002For sterile sample before randomization and before availability of multiplex molecular microbiology results.","18 Years",{"count":59,"type":23},250,[61],"NA","The goal of this clinical trial is to learn whether integrating rapid multiplex molecular microbiology results with predefined clinical and laboratory criteria into an antimicrobial stewardship program improves antimicrobial use in hospitalized adults receiving empiric high-impact antimicrobial therapy.\n\nThe main questions it aims to answer are:\n\nDoes this strategy reduce the duration of exposure to high-impact antimicrobial therapy compared with standard antimicrobial stewardship practice? Does this strategy improve the appropriateness of antimicrobial treatment? Does this strategy affect clinical outcomes, including hospital readmission, intensive care unit admission, infection recurrence, mortality, and healthcare costs? Researchers will compare a protocolized antimicrobial stewardship strategy that incorporates multiplex molecular microbiology results and predefined clinical criteria with the standard antimicrobial stewardship strategy currently used in the hospital.\n\nParticipants will:\n\nReceive antimicrobial management according to the stewardship strategy assigned to their hospital unit during the study period.\n\nUndergo molecular microbiology testing and routine clinical and laboratory assessments as part of standard hospital care when indicated.\n\nBe followed to evaluate antimicrobial exposure, treatment appropriateness, safety outcomes, hospital readmission, intensive care unit admission, infection recurrence, mortality, and healthcare costs.",[64,65,30,66],"Infection","Antimicrobial Stewardship Program","Multiplex PCR",[66,68,69,30,70,71,72,73,74],"Molecular Microbiology","Antimicrobial Stewardship","Antibiotic Optimization","Antimicrobial Therapy","infectious Diseases","Cluster Randomized Trial","Crossover Trial","2026-07-01",{"date":77,"type":40},"2026-07-06",{"date":79,"type":40},"2026-04-10",{"date":81,"type":23},"2027-06",{"name":83,"class":47},"Maria Espinosa Perez",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":48},"100559651","monitoring-of-antimicrobial-resistance-based-on-metagenomics-analyses-in-pneumonia-patients-100559651","NCT06566898","Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients","Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients: a Genomic Epidemiology Study","Inclusion Criteria:\n\n* Patients clinically diagnosed as severe pneumonia and mild pneumonia are diagnosed according to the Guidelines for the diagnosis and Treatment of community-acquired pneumonia in Adults (2019 edition) formulated by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), who meet 1 of the following major criteria or ≥3 minor criteria can be diagnosed. The diagnostic criteria for severe and mild pneumonia in children were adopted by the British Thoracic Society (BTS) in 2011.\n* Clinical examination was performed, and there was biospecimen (nasopharyngeal swab, oropharyngeal swab, bronchoalveolar lavage fluid, sputum, blood, hydrothorax, lung tissue) remaining in the clinical microbiological examination.\n\nExclusion Criteria:\n\n* Patients whose biological samples may be contaminated;\n* Patients with alveolar lavage fluid or hydrothorax volume less than 200μl.",{"count":92,"type":23},800,"OBSERVATIONAL","Monitoring of antimicrobial resistance (AMR) based on metagenomics analyses in pneumonia patients is critical for optimizing clinical diagnosis and treatment and improving clinical prognosis. This study is designed to ask the following key questions:\n\n1. What is the microbiome maps of patients with severe pneumonia and mild pneumonia ?\n2. How many pathogen resistance genes are carrying in severe pneumonia and mild pneumonia ?\n3. What is the genetic diversity of key pathogens detected in severe pneumonia and mild pneumonia during 2019-2025?",[96,97,98,30],"Pneumonia","Next-generation Sequencing","Microbiome",[96,100,98,30],"Next-generation sequencing","2026-04-21",{"date":103,"type":40},"2026-04-23",{"date":105,"type":40},"2024-08-01",{"date":107,"type":23},"2026-09-30",{"name":109,"class":47},"Shanghai General Hospital, China",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100610957","a-multicentre-study-of-wastewater-and-antibiotic-resistance-in-care-homes-100610957","NCT07234331","A Multicentre Study of Wastewater and Antibiotic Resistance in Care Homes.","Multicentre Study Analysing Wastewater to Monitor Bacterial Resistance to Antibiotics in Residential Care Homes for Elderly Dependent.","E-FLUENT","Inclusion Criteria:\n\n* Residents present on the day of sampling (D0 or D+1) in a facility selected during randomization, without criteria regarding length of stay in the facility, and whose health status on the day of the survey permits it;\n* Residents who, based on clinical criteria (including an MMSE greater than or equal to 20), are deemed by the nursing home team to be able to understand the issues of the study and to express an informed non-opposition; OR Residents who the nursing home team considers unable to express an informed non-objection but who have a legal representative, a trusted person, or a loved one capable of understanding the information and expressing an informed non-objection.\n\nResidents may be included regardless of the presence of infection, diarrheal stools, antibiotic use or any other treatment, or health status.\n\nParticipants in this study may participate in other research projects concurrently.\n\nExclusion Criteria: Health and medico-social facilities not considered nursing homes (e.g., FAM, MAS, etc.);\n\n* Residents whose health status is incompatible with performing the procedure on the day of the survey (e.g., end-of-life with comfort care);\n* Residents with a Mini Mental State Examination (MMSE) score of less than or equal to 20, or without an MMSE score but who, according to nursing home professionals, are unable to provide an informed non-objection and who do not have a legal representative, trusted person, or relative capable of receiving information and providing an informed non-objection;\n* Residents, regardless of their MMSE score, who refuse to have the sample taken on the day of the survey even if their legal repre",{"count":119,"type":23},1600,"This study aims to model the relationship between the prevalence of ESBL-E and CPE carriage among nursing home residents and their respective concentrations in wastewater discharged from the facility.",[30],[123,124,125],"Nursing home","Wastewater","Surveillance","2026-04-13",{"date":128,"type":40},"2026-04-16",{"date":130,"type":40},"2026-03-16",{"date":132,"type":23},"2027-06-30",{"name":134,"class":47},"Nantes University Hospital",2,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":18,"minAge":57,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":24,"phases":145,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100631662","phase-3-the-effect-of-adjunctive-melatonin-with-colistin-in-patients-with-multidrug-resistant-gram-negative-bacterial-infections-100631662","NCT07503600","The Effect of Adjunctive Melatonin With Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections","Inclusion Criteria:\n\n* • Confirmed diagnosis of infection caused by multidrug-resistant Gram-negative bacteria based on microbiological culture and sensitivity testing\n\n  * Patients receiving intravenous colistin therapy according to institutional protocols\n  * Clinical diagnosis of sepsis or severe infection in accordance with established critical care criteria\n\nExclusion Criteria:\n\n* • Pregnancy or lactation\n\n  * Terminal medical or surgical illness (e.g., advanced malignancy)\n  * Severe chronic liver disease or end-stage renal failure\n  * Impaired cognitive function or active psychiatric illness under treatment\n  * Known hypersensitivity to melatonin\n  * Use of melatonin within 48 hours prior to enrollment","70 Years",{"count":144,"type":23},70,[146],"PHASE3","This study evaluates whether adding melatonin to standard colistin therapy improves outcomes in patients with multidrug-resistant (MDR) Gram-negative bacterial infections. These infections are difficult to treat and are associated with high morbidity and mortality, particularly in critically ill patients.\n\nColistin is often used as a last-line antibiotic for these infections; however, its effectiveness may be limited, and it is associated with side effects such as kidney injury. Melatonin, a naturally occurring hormone, has antioxidant, anti-inflammatory, and immune-modulating properties that may enhance the effectiveness of antibiotics and reduce treatment-related complications.\n\nIn this randomized, double-blind, placebo-controlled study, adult patients receiving colistin will be assigned to receive either melatonin or a placebo in addition to standard care. The study will assess whether melatonin improves oxidative stress, infection control, and clinical outcomes while maintaining safety.",[149,30],"Multidrug-Resistant Gram-Negative Bacterial Infections",[151,152,153,154],"Gram-Negative Infections","multidrug resistance","colistin","gram negative infections","NOT_YET_RECRUITING","2026-03-26",{"date":158,"type":40},"2026-03-31",{"date":156,"type":23},{"date":161,"type":23},"2026-08-26",{"name":163,"class":47},"Ain Shams University"]